Abstract

Public Health Relevance

Given our long-term goal to discover new therapeutic approaches that can improve patient outcomes, we will investigate a novel therapeutic strategy, intranasal drug delivery, aiming to inhibit the invasion of glioma cells. The proposed studies are the first, to our knowledge, to simultaneously target two clinically relevant hallmarks associated with malignant glioma: angiogenesis and invasion. These data should provide exploratory information leading towards the development of novel therapies for glioma patients.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21NS065380-01
Application #
7641396
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Fountain, Jane W
Project Start
2009-07-16
Project End
2011-06-30
Budget Start
2009-07-16
Budget End
2010-06-30
Support Year
1
Fiscal Year
2009
Total Cost
$265,353
Indirect Cost

  Institution

Name
New York University
Department
Pathology
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016

  Publications

Esencay, Mine; Sarfraz, Yasmeen; Zagzag, David (2013) CXCR7 is induced by hypoxia and mediates glioma cell migration towards SDF-1?. BMC Cancer 13:347
Williams, Susan C; Karajannis, Matthias A; Chiriboga, Luis et al. (2011) R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1? upregulation in adult glioma. Acta Neuropathol 121:279-81